<DOC>
	<DOCNO>NCT02661464</DOCNO>
	<brief_summary>The purpose study ass long-term safety profile Ad26.ZEBOV MVA-BN-Filo participant previously expose vaccine Phase 1 , 2 , 3 clinical study .</brief_summary>
	<brief_title>Long-term Safety Follow-up Participants Exposed Candidate Ebola Vaccines Ad26.ZEBOV and/or MVA-BN-Filo</brief_title>
	<detailed_description>This multi-country , prospective , long-term clinical safety study collection serious adverse event pregnancy outcomes follow administration Ad26.ZEBOV and/or MVA-BN-Filo vaccine among participant enrol Phase 1 , 2 3 clinical study . The safety data collect 3 cohort ; Cohort 1- adult pediatric participant receive Ad26.ZEBOV and/or MVA-BN-Filo Phase 1 , 2 3 clinical study ( adult , adolescent child ) , Cohort 2- Female participant become pregnant estimate conception within 28 day vaccination MVA-BN-Filo within 3 month vaccination Ad26.ZEBOV follow end pregnancy pregnancy outcome ( Cohort 2 ) . After end pregnancy , female participant continue follow Cohort 1 . Cohort 3 - child bear female participant expose Ad26.ZEBOV and/or MVA-BN-Filo become pregnant estimate conception within 28 day vaccination MVA-BN-Filo within 3 month vaccination Ad26.ZEBOV . Safety data collect consent participant .</detailed_description>
	<mesh_term>Hemorrhagic Fever , Ebola</mesh_term>
	<mesh_term>Hemorrhagic Fevers , Viral</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Male female participate Phase 1 , 2 3 clinical study Human adenovirus serotype 26 ( Ad26 ) express Ebola virus Mayinga variant glycoprotein ( Ad26.ZEBOV ) and/or Modified Vaccinia Virus Ankara ‐ Bavarian Nordic Filo‐vector ( MVABNFilo ) expose Ad26.ZEBOV and/or MVABNFilo ( Cohort 1 ) Female participate Phase 1 , 2 3 clinical study Ad26.ZEBOV and/or MVABNFilo become pregnant estimate conception within 28 day vaccination MVABNFilo within 3 month vaccination Ad26.ZEBOV ( Cohort 2 ) Child bear female participant expose Ad26.ZEBOV and/or MVABNFilo Phase 1 , 2 , 3 clinical study become pregnant estimate conception within 28 day vaccination MVABNFilo within 3 month vaccination Ad26.ZEBOV ( Cohort 3 ) Must sign inform consent form current study ( legally acceptable representative must sign ) indicate understands purpose , procedure require , study willing participate study ( let child participate ) ; Assent also require child capable understanding nature study ( typically 7 year age old ) No exclusion beyond meet inclusion criterion</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>71 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Healthy</keyword>
	<keyword>Ebola virus</keyword>
	<keyword>Ebola virus disease ( EVD )</keyword>
	<keyword>Filoviruses</keyword>
	<keyword>Safety</keyword>
	<keyword>Human adenovirus serotype 26 ( Ad26 ) express Ebola virus Mayinga variant glycoprotein ( Ad26.ZEBOV )</keyword>
	<keyword>Modified Vaccinia Virus Ankara ‐ Bavarian Nordic Filo‐vector ( MVA‐BN Filo )</keyword>
	<keyword>Hemorrhagic fever</keyword>
</DOC>